OTCM
PMDI
Market cap14mUSD
Jul 10, Last price
2.49USD
Name
Psychemedics Corp
Chart & Performance
P/E
—
P/S
0.74
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.21%
Rev. gr., 5y
-12.18%
Revenues
20m
-10.92%
Net income
-2m
L-55.20%
CFO
929k
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1986 and based in Acton, Massachusetts, Psychemedics Corporation specializes in providing comprehensive drug abuse detection services. The company operates across the United States, Brazil, and various international locations, employing hair sample analysis to identify a broad spectrum of substances. Their rigorous testing methodology involves both initial screening and confirmatory analysis through mass spectrometry, adhering to recognized industry standards. Psychemedics' analytical capabilities cover a wide array of drugs, including common illicit substances like cocaine, marijuana, and PCP. They also detect various amphetamines, such as ecstasy, eve, and Adderall, along with a comprehensive list of opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. Furthermore, their tests identify synthetic cannabinoids (e.g., K2, Spice, Blaze), benzodiazepines (like Xanax, Valium, and Ativan), nicotine, and Fentanyl. The results of their analyses offer more than just a positive or negative finding; they provide quantitative data indicating the approximate amount of drug consumed. Crucially, the tests also yield historical information that can reveal an individual's drug use patterns over an extended period. Psychemedics serves a diverse clientele, including employers seeking applicant and employee drug screening, treatment professionals, law enforcement agencies, school administrators, and parents concerned about potential substance use by their children.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||